According to Bloomberg Ratings, the seven analysts that track Relay Therapeutics, Inc. (NASDAQ:RLAY) have assigned the company a rating of “Moderate Buy” as the company’s overall consensus recommendation. There have been six recommendations made by experts in equity research: one to buy the stock, one to sell it, and one to keep it in one’s portfolio. The $34.86 price target that has been established as the average 12-month price target for the company by analysts who have published reports on it in the last year has been established. This price target was established by analysts who published reports on the company in the last year.
The results of RLAY studies have been compiled and presented in reports by a diverse range of research organizations. The research note Barclays published on September 30 contained an announcement that the company would begin covering shares of Relay Therapeutics. They have assigned an “equal weight” rating to the stock and have projected that it will reach $23.00 in price. HC Wainwright decreased their price objective on shares of Relay Therapeutics from $50.00 to $43.00 in a research report that was published on Monday, November 7. HC Wainwright maintained their “buy” rating on the stock despite the price objective decrease.
The NASDAQ RLAY market opened for trading on Tuesday with a price of $20.77 per share. A price-to-earnings ratio of -7.81 and a beta value of 1.01 are both associated with the business. The total value of the company, as measured by its market capitalization, is $2.51 billion. The moving average of the company’s stock price over the past two hundred days is $20.24, and the moving average over the last fifty days is $17.38. Over the last 52 weeks, the price of a share of Relay Therapeutics has ranged from a low of $12.65 to a high of $35.36.
The most recent quarterly earnings report for Relay Therapeutics, located on the stock market under the ticker symbol “RLAY,” was released on November 3. You can find this report under the ticker symbol “RLAY.” The company reported earnings per share (EPS) for the quarter at $0.76, which was $0.06 lower than the consensus expectation of $0.71. The revenue for the quarter came in at $0.34 million, which was significantly lower than the $0.50 million that industry analysts had anticipated it would be. In the case of Relay Therapeutics, the company’s profit margin and return on equity were below 20%, coming in at 17.136.40% and 21.42%, respectively. Sell-side analysts have forecasted that Relay Therapeutics will bring in earnings of -2.81 cents per share for the current fiscal year.
Additionally, on November 1, an insider at Relay Therapeutics named Donald A. Bergstrom sold 8,000 shares of the company’s stock. A total price of $182,000.00 was received for the sale of the shares, which works out to an average selling pr